Business
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK, May 09, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates.
About this update from Neurogene Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":331,"url":"https://media.zenfs.com/en/business-wire.com/77ae3982cbb7b9a391c2266477232f7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZiEqq5Kk2yGN.qeLqs2qsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/77ae3982cbb7b9a391c2266477232f7d","width":480,"height":331}},"lazy":false},{"type":"text","content":"On track to provide registrational trial plan update for NGN-401 gene therapy for Rett syndrome in the first half of 2025","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"Continues to plan to provide clinical data update from ongoing NGN-401 Phase 1/2 trial in the second half of 2025","length":113,"tagName":"p","attribs":{}},{"type":"text","content":"Cash runway into the second half of 2027","length":40,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, May 09, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates.","length":305,"tagName":"p"},{"type":"text","content":""We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an update on our plans during the first half of this year," said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "As we work to finalize our proposed trial design to differentiate and position the product candidate as potentially best-in-class for future commercialization, we appreciate the continued collaboration with the FDA. We also advanced the Phase 1/2 trial of NGN-401, and we look forward to sharing updated interim clinical data from the trial in the second half of 2025."","length":676,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Recent Highlights, and Anticipated Milestones","length":68,"tagName":"p"},{"type":"text","content":"Phase 1/2 Trial of NGN-401 Gene Therapy for Treatment of Rett Syndrome","length":70,"tagName":"p"},{"type":"text","content":"NGN-401 is currently being evaluated in an ...